Clinical trials
CAR T Cell clinical trials
Below are recruiting car t cell clinical trials, each written for real people, not researchers. We’re tracking 645 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07168486Enrolling by invitationPhase 1
CAR T-cells targeting CD19, CD20, and CD22 for lymphoma
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
Baltimore, MarylandAges 18 years+ - NCT07838714RecruitingPhase 1
Cord blood CAR-T cells for relapsed B-cell leukemia
This trial tests a new type of personalized cell therapy using your own immune cells (called CAR-T cells) that are designed to find and attack leukemia cells that have certain markers (CD19 and CD22). It is for people whose leukemia has returned or not responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05947487RecruitingPhase 1/Phase 2
CAR-T treatment for CD70-positive advanced solid tumors
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
Beijing, Iotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75 - NCT06101082RecruitingPhase 1
Testing anti-HER2-CAR-T cells for advanced solid tumors
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
Shenyang, LiaoningAges 18–70 - NCT06352281RecruitingPhase 1/Phase 2
CAR-T cell therapy for chronic or hard-to-treat ITP
This trial tests a new type of immune cell therapy (CAR-T cells) for people with chronic or refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if this treatment can safely raise platelet counts and reduce bleeding risk.
Kunming, YunnanAges 8–75 - NCT06728189RecruitingPhase 1
CD70-targeted CAR-NKT cells for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
BeijingAges 18–75 - NCT06337474RecruitingEarly Phase 1
CD19 CAR NK cells for hard-to-treat immune thrombocytopenia
This study tests whether a new treatment using specially designed immune cells (CD19 CAR NK cells) can help people with immune thrombocytopenia (ITP) that has not improved with standard treatments. It aims to improve platelet counts and reduce bleeding risk.
Changzhou, JiangsuAges 18–65 - NCT06815432RecruitingPhase 1
GPC-3 CAR T cells for recurrent GPC-3 positive glioblastoma
This trial tests whether a special type of immune cell (called CAR T cells) can fight a brain tumor called glioblastoma that has come back. The cells are made to target a protein on the tumor cells, and the study will see if this treatment is safe and helpful.
Houston, TexasAges 21–70 - NCT06464679RecruitingPhase 1
CD19 CAR NK cells for autoimmune diseases
This trial tests a new type of immune cell therapy (CD19 CAR NK cells) for people with certain autoimmune diseases that have not responded to standard treatments. The goal is to see if these cells can safely reduce disease activity.
ShanghaiAges 18–65 - NCT06513429Recruiting
IM19 CAR-T cell therapy for tough lupus cases
This trial tests whether a new type of immune cell therapy, called IM19 CAR-T, can help people with lupus that hasn't gotten better with standard treatments. It is designed for people ages 18 to 65 with moderate to severe disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT05544526RecruitingPhase 1
CAR T cell treatment for brainstem spinal cord tumor in children
This Phase 1 trial tests CAR T cells designed to attack a specific target (GD2) on a rare childhood brain/spinal tumor called DMG with a certain gene change (H3K27M). It is mainly designed to check safety and early signs of effectiveness after prior treatments.
LondonAges Up to 16 years - NCT04290000Recruiting
Share samples after CAR-T treatment at Montpellier hospital
This study collects and stores biological samples from people who have been treated with CAR-T cells at the University Hospital of Montpellier. Your samples can help researchers learn more about treatment effects and safety.
MontpellierAges 18 years+ - NCT02917083RecruitingPhase 1
CD30 CAR T cell treatment for hard-to-treat lymphomas
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
Houston, TexasAges 12–75 - NCT06911710RecruitingPhase 1/Phase 2
Car-T therapy for relapsed blood cancers
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06643221RecruitingEarly Phase 1
Exercise as a booster for cell therapy treatments
This trial tests whether exercise and a heart medicine called isoproterenol can help your immune system work better with donor cell therapies. It may show how to make these treatments more effective.
Tucson, ArizonaAges 21–55 - NCT05240950RecruitingPhase 1
CAR-T cell therapy for colorectal cancer in the liver
This Phase 1 study tests an anti-CEA CAR-T cell treatment for people whose colorectal cancer spread to the liver but has been surgically removed with no visible remaining tumor. It aims to see if the treatment can better prevent the cancer from coming back, especially when early warning tests suggest leftover cancer cells.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06010472RecruitingEarly Phase 1
Car-NK cell therapy for lupus
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
ShanghaiAges 18–65 - NCT06515262Recruiting
Testing anti-BCMA-GPRC5D CAR-T cells for relapsed multiple myeloma
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
Kunming, Kunming, YunnanAges 18–75 - NCT07477912RecruitingPhase 1/Phase 2
BCMA-targeting CAR-T for relapsed/refractory multiple myeloma
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
MinskAges 18 years+ - NCT03937544RecruitingPhase 2/Phase 3
Study of your own CAR-T cells for hard-to-treat B-ALL
This trial tests a treatment made from your own immune cells (CAR-T cells) to help control relapsed or refractory B-ALL. It is designed for people whose disease has come back or not responded to prior therapy, and who have specific brain/spinal fluid and organ health requirements.
Bandar Tun Razak, Kuala LumpurAges 13–65 - NCT06865664RecruitingPhase 1
Engineered immune cells for relapsed rhabdomyosarcoma in youth
This early-phase trial tests a new immune cell therapy (CAR T cells) for children and young adults whose rhabdomyosarcoma has returned or not responded to standard treatments. The goal is to see if these specially engineered cells can find and attack the cancer.
Bethesda, MarylandAges 3–39 - NCT06786533RecruitingPhase 1
CAR-T cells for hard-to-treat AML
This study tests a new treatment made from your own immune cells, engineered to find and attack AML cells. It is for patients whose leukemia has not responded to standard therapy or has come back after treatment, including after a stem cell transplant.
Houston, TexasAges 12 years+ - NCT06481228Recruiting
TKI plus chemo and CAR-T for newly diagnosed Ph+ ALL
This trial tests combining a targeted drug (TKI) with chemotherapy and then CAR-T cells for adults who are newly diagnosed with Philadelphia chromosome-positive ALL. The goal is to see if this combination is safe and effective.
TianjinAges 18 years+ - NCT06503107RecruitingPhase 1/Phase 2
Nanobody-based CAR-T cells for multiple myeloma
This trial tests a new type of CAR-T cell therapy that targets a protein called BCMA on your myeloma cells. It is for people with multiple myeloma that has not responded to or has come back after several prior treatments.
Wuhan, HubeiAges 18–75
Hear when a new CAR T Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for car t cell?
- Yes. Clin2 currently lists 645 recruiting car t cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a car t cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a car t cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.